What is Leerink Partnrs’ Forecast for Quanterix Q1 Earnings?

Quanterix Co. (NASDAQ:QTRX) – Leerink Partnrs decreased their Q1 2025 earnings per share estimates for Quanterix in a report released on Monday, March 17th. Leerink Partnrs analyst P. Souda now expects that the company will post earnings of ($0.69) per share for the quarter, down from their previous estimate of ($0.58). The consensus estimate for Quanterix’s current full-year earnings is ($0.98) per share. Leerink Partnrs also issued estimates for Quanterix’s Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.49) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.21) EPS and FY2026 earnings at ($1.05) EPS.

Separately, Canaccord Genuity Group dropped their price objective on Quanterix from $20.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday.

Quanterix Price Performance

QTRX opened at $7.20 on Thursday. The company’s 50 day simple moving average is $8.32 and its two-hundred day simple moving average is $10.90. Quanterix has a 1-year low of $6.30 and a 1-year high of $27.37. The firm has a market capitalization of $277.37 million, a price-to-earnings ratio of -6.79 and a beta of 1.34.

Quanterix (NASDAQ:QTRX) last issued its earnings results on Monday, March 17th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). The business had revenue of $35.16 million during the quarter, compared to analyst estimates of $34.93 million. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Resona Asset Management Co. Ltd. acquired a new stake in shares of Quanterix during the 4th quarter worth about $55,000. Tower Research Capital LLC TRC raised its holdings in Quanterix by 219.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company’s stock worth $61,000 after purchasing an additional 3,915 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Quanterix in the 4th quarter valued at $66,000. Canada Pension Plan Investment Board grew its stake in Quanterix by 64.5% during the 4th quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company’s stock worth $108,000 after buying an additional 4,000 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new position in shares of Quanterix in the 4th quarter valued at approximately $108,000. 86.48% of the stock is owned by institutional investors and hedge funds.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.